Bill
HR 8205
Accelerating Access to Critical Therapies for ALS Reauthorization Act of 2026
119th Congress
Introduced by Alma Adams and 97 co-sponsors
HR 8205 extends federal ALS treatment acceleration programs through 2031, maintaining expedited FDA review processes and research funding for amyotrophic lateral sclerosis therapies.
Received in the Senate. Read twice. Placed on Senate Legislative Calendar under General Orders. Calendar No. 466.